Oruka Therapeutics (ORKA) Equity Average (2011 - 2026)
Oruka Therapeutics' quarterly Equity Average came in at $479.3 million in Q1 2026, up 28.34% year-on-year from $373.5 million in Q1 2025, and little changed quarter-over-quarter from $479.4 million in Q4 2025.
Oruka Therapeutics has reported Equity Average for 16 years, with the latest figure at $479.3 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 28.34% year-over-year to $479.3 million; the trailing twelve-month figure through Mar 2026 stood at $479.3 million (up 28.34% YoY), and the FY2025 full-year result was $427.1 million, up 103.74% from the prior year.
- Equity Average for Q1 2026 stood at $479.3 million, roughly flat from $479.4 million in the prior quarter.
- The five-year high for Equity Average was $479.4 million in Q4 2025, with the low at -$18.0 million in Q2 2024.
- Average Equity Average over 5 years is $173.9 million, with a median of $46.5 million recorded in 2022.
- Year-over-year, Equity Average sank 145.18% in 2024 and surged 2393.06% in 2025.
- Tracing ORKA's Equity Average over 5 years: stood at $42.2 million in 2022, then declined by 11.15% to $37.5 million in 2023, then jumped by 866.27% to $362.3 million in 2024, then soared by 32.31% to $479.4 million in 2025, then decreased by 0.01% to $479.3 million in 2026.
- The last three Equity Average figures came in at $479.3 million (Q1 2026), $479.4 million (Q4 2025), and $415.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | 479.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 479.33 Mn |
| Dec 31, 2025 | 479.36 Mn |
| Sep 30, 2025 | 415.22 Mn |
| Jun 30, 2025 | 354.18 Mn |
| Mar 31, 2025 | 373.47 Mn |
| Dec 31, 2024 | 362.29 Mn |
| Sep 30, 2024 | 156.69 Mn |
| Jun 30, 2024 | -18.02 Mn |
| Mar 31, 2024 | 14.98 Mn |
| Dec 31, 2023 | 37.49 Mn |
| Sep 30, 2023 | 38.60 Mn |
| Jun 30, 2023 | 39.88 Mn |
| Mar 31, 2023 | 41.10 Mn |
| Dec 31, 2022 | 42.20 Mn |
| Sep 30, 2022 | 43.85 Mn |
| Jun 30, 2022 | 46.45 Mn |
| Mar 31, 2022 | 49.49 Mn |
| Dec 31, 2021 | 53.82 Mn |
| Sep 30, 2021 | 58.90 Mn |
| Jun 30, 2021 | 63.56 Mn |
| Mar 31, 2021 | 56.22 Mn |
| Dec 31, 2020 | 48.49 Mn |
| Sep 30, 2020 | 30.38 Mn |
| Jun 30, 2020 | 8.31 Mn |
| Mar 31, 2020 | 6.96 Mn |
| Dec 31, 2019 | 8.20 Mn |
| Sep 30, 2019 | 8.99 Mn |
| Jun 30, 2019 | 8.25 Mn |
| Mar 31, 2019 | 6.68 Mn |
| Dec 31, 2018 | 6.75 Mn |
| Sep 30, 2018 | 8.23 Mn |
| Jun 30, 2018 | 10.03 Mn |
| Mar 31, 2018 | 10.66 Mn |
| Dec 31, 2017 | 12.31 Mn |
| Sep 30, 2017 | 14.55 Mn |
| Jun 30, 2017 | 16.39 Mn |
| Mar 31, 2017 | 20.12 Mn |
| Dec 31, 2016 | 24.34 Mn |
| Sep 30, 2016 | 28.69 Mn |
| Jun 30, 2016 | 32.74 Mn |
| Mar 31, 2016 | 36.33 Mn |
| Dec 31, 2015 | 39.58 Mn |
| Sep 30, 2015 | 42.43 Mn |
| Jun 30, 2015 | 27.94 Mn |
| Mar 31, 2015 | 13.43 Mn |
| Dec 31, 2014 | 15.97 Mn |
| Sep 30, 2014 | 18.26 Mn |
| Jun 30, 2014 | 20.43 Mn |
| Mar 31, 2014 | 18.56 Mn |
| Dec 31, 2013 | 16.98 Mn |
| Sep 30, 2013 | 19.20 Mn |
| Jun 30, 2013 | 11.67 Mn |
| Mar 31, 2013 | 3.11 Mn |
| Dec 31, 2012 | 3.04 Mn |
| Sep 30, 2012 | 3.23 Mn |
| Jun 30, 2012 | 3.82 Mn |
| Mar 31, 2012 | 5.04 Mn |
| Dec 31, 2011 | 5.73 Mn |
| Sep 30, 2011 | 6.64 Mn |